• Exploration of Targeted Anti-tumor Therapy

    eISSN: 2692-3114
    Co-EiC: Graham Packham, PhD, University of Southampton
    Co-EiC: Nicola Normanno, MD, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale
    Frequency: Bimonthly
    APC: No Article Processing Charge
    Publishing Model: Open Access
    Peer Review Model: Single Blind
    Indexing & Archiving: CAS, DOAJ, Portico, ResearchGate, CNKI Scholar, J-Gate, etc
    Follow the journal:
    Follow the journal:
    Articles
    Open Access
    Review
    Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
    The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In r...
    Stefano Cavalieri ... Laura D. Locati
    Online First: December 07, 2021 Explor Target Antitumor Ther. 2021;2:Online First
    DOI: https://doi.org/10.37349/etat.2021.00062
    This article belongs to the special issue Immunotherapy in Cancer Patients
    View:63
    Download:8
    Times Cited: 0
    Open Access
    Review
    The clinical advances of proteolysis targeting chimeras in oncology
    Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for the...
    Hao Xie ... Jason B. Fleming
    Online First: December 02, 2021 Explor Target Antitumor Ther. 2021;2:Online First
    DOI: https://doi.org/10.37349/etat.2021.00061
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:88
    Download:20
    Times Cited: 0
    Open Access
    Review
    Proteolysis-targeting chimeras and their implications in breast cancer
    Breast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estro...
    Angeles C. Tecalco-Cruz ... Alberto Rojas-Ochoa
    Online First: November 16, 2021 Explor Target Antitumor Ther. 2021;2:Online First
    DOI: https://doi.org/10.37349/etat.2021.00060
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:173
    Download:32
    Times Cited: 0
    Open Access
    Review
    A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
    Patients with unresectable biliary tract carcinomas (BTCs) have a poor prognosis with a median overall survival of fewer than 12 months following systemic chemotherapy. In recent years, the identifi...
    Giacomo Aimar ... Massimo Di Maio
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:448-464
    DOI: https://doi.org/10.37349/etat.2021.00056
    This article belongs to the special issue Precision Medicine for Cholangiocarcinoma
    View:256
    Download:47
    Times Cited: 0
    Open Access
    Review
    Targeted therapy of multiple myeloma
    Multiple myeloma (MM) is a malignant proliferative disease of monoclonal plasma cells (PCs) and is characterized by uncontrolled proliferation of PCs and excessive production of specific types of im...
    Shan Zhou, Renxi Wang
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:465-480
    DOI: https://doi.org/10.37349/etat.2021.00057
    View:154
    Download:28
    Times Cited: 0
    Open Access
    Original Article
    Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center
    Aim: Since SARS-CoV-2 infection rapidly spread around the world, Italy has quickly become one of the most affected countries. Healthcare systems introduced strict infection control measures to ensu...
    Maristella Bungaro ... Silvia Novello
    Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:481-489
    DOI: https://doi.org/10.37349/etat.2021.00058
    This article belongs to the special issue COVID-19 and Cancer
    View:157
    Download:20
    Times Cited: 0
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” ...
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273-312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:8181
    Download:1147
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi...
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71-100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:6197
    Download:336
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell ...
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131-152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:4417
    Download:180
    Open Access
    Review
    Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms
    Cancer development is frequently associated with dysregulation of mRNA translation to enhance both increased global protein synthesis and translation of specific mRNAs encoding oncoproteins. Thus, t...
    Joe Taylor ... Graham Packham
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:3-25
    DOI: https://doi.org/10.37349/etat.2020.00002
    View:3163
    Download:90
    Open Access
    Review
    Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
    The Fanconi anaemia (FA) pathway is an important mechanism for cellular DNA damage repair, which functions to remove toxic DNA interstrand crosslinks. This is particularly relevant in the context of...
    Sarah J Taylor ... Simon P Langdon
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:26-52
    DOI: https://doi.org/10.37349/etat.2020.00003
    View:3156
    Download:93
    Times Cited: 0
    Open Access
    Review
    Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma
    Colorectal carcinoma (CRC) is an heterogeneous disease in which different genetic alterations play a role in its pathogenesis and progression and offer potential for therapeutic intervention. The re...
    Anna Maria Rachiglio ... Nicola Normanno
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:53-70
    DOI: https://doi.org/10.37349/etat.2020.00004
    View:2874
    Download:101
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” ...
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273-312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:8181
    Download:1147
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi...
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71-100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:6197
    Download:336
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell ...
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131-152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:4417
    Download:180
    Open Access
    Review
    PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors
    BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance. More recently, BCL-XL has also been identified...
    Peiyi Zhang ... Guangrong Zheng
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:259-272
    DOI: https://doi.org/10.37349/etat.2020.00017
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:2234
    Download:133
    Open Access
    Review
    Novel approaches for the rational design of PROTAC linkers
    Proteolysis targeting chimeras (PROTACs) represent a promising class of hetero-bivalent molecules that facilitate ubiquitination of a target protein by simultaneously binding and bringing together b...
    Almaz Zagidullin ... Emil Bulatov
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381-390
    DOI: https://doi.org/10.37349/etat.2020.00023
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:1723
    Download:104
    Open Access
    Review
    Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma
    Colorectal carcinoma (CRC) is an heterogeneous disease in which different genetic alterations play a role in its pathogenesis and progression and offer potential for therapeutic intervention. The re...
    Anna Maria Rachiglio ... Nicola Normanno
    Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:53-70
    DOI: https://doi.org/10.37349/etat.2020.00004
    View:2874
    Download:101
    Open Access
    Review
    Current strategies for the design of PROTAC linkers: a critical review
    PROteolysis TArgeting Chimeras (PROTACs) are heterobifunctional molecules consisting of two ligands; an “anchor” to bind to an E3 ubiquitin ligase and a “warhead” ...
    Robert I. Troup ... Matthias G. J. Baud
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273-312
    DOI: https://doi.org/10.37349/etat.2020.00018
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:8181
    Download:1147
    Open Access
    Review
    The impact of tumour pH on cancer progression: strategies for clinical intervention
    Dysregulation of cellular pH is frequent in solid tumours and provides potential opportunities for therapeutic intervention. The acidic microenvironment within a tumour can promote migration, invasi...
    Carol Ward ... Simon P Langdon
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71-100
    DOI: https://doi.org/10.37349/etat.2020.00005
    View:6197
    Download:336
    Open Access
    Review
    Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer
    Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains...
    Sosmitha Girisa ... Ajaikumar B. Kunnumakkara
    Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:313-342
    DOI: https://doi.org/10.37349/etat.2020.00019
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    View:876
    Download:29
    Open Access
    Review
    Role of liquid biopsy for thoracic cancers immunotherapy
    Immunotherapy has shifted the therapeutic landscape in thoracic cancers. However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the...
    Raimondo Di Liello ... Paloma Martín-Martorell
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:183-199
    DOI: https://doi.org/10.37349/etat.2020.00012
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:1504
    Download:27
    Open Access
    Original Article
    Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients
    Aim: Single biomarker diagnostic test of BRAFV600 locus in metastatic melanoma is mandatory for treatment decision; however, multiple-gene based techniques, such as targeted next-generation sequenc ...
    Paola Castillo ... Cristina Teixido
    Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:101-108
    DOI: https://doi.org/10.37349/etat.2020.00006
    View:1159
    Download:25
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell ...
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131-152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:4417
    Download:180
    Special Issues